Venetoclax is an orally bioavailable small-molecule inhibitor of Bcl-2 that leads to CLL cell apoptosis.16,17 Venetoclax therefore would be expected to sensitize CLL cells to death by other discrete mechanisms. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.